Interestingly, CD9 was significantly co-localized with breast cancer-associated HPA-positive plasma-enriched sEVs compared to sEVs derived from healthy individuals compared to patients with non-metastatic cancer (p < 0.05). This evidence concerns the gene CD9 and metastatic malignant neoplasm.